OpenAI is going into the drug business — not by discovering molecules itself, but by buying the company that keeps drug programs on the rails. On Monday, the AI giant announced it has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical teams manage the long, expensive grind of drug development. The team and its technology will join Rosalind, OpenAI's suite of models and tools for biology and drug discovery.
Financial terms of the deal were not disclosed.
Buying the operating layer, not the molecule
Most AI-in-biology startups pitch molecule discovery: let the model find the drug. Orchestra Bio's pitch was different — manage the program around the molecule. The company describes its platform as an "agentic operating layer" that spans multiple stages of drug development, software that sits on top of a drug program and coordinates work across phases, with AI agents handling tasks alongside human scientists.
According to OpenAI, the startup's platform was designed to let researchers hand off hands-on work to agents: monitoring studies, tracking development timelines, and spotting possible delays before they become expensive. The goal is to connect scientific findings with concrete decisions and next steps in the pipeline — the unglamorous operational work where drug programs quietly stall.
Orchestra was founded around October 2022 by Ashoka Rajendra, who drew on biology research and life-sciences software work to build the platform. The company raised its seed financing in late 2022, making this roughly a four-year journey from first check to acquisition by the world's most valuable AI lab.
Rosalind is becoming a full life-sciences business
The acquisition slots directly into Rosalind, the life-sciences offering OpenAI has been assembling this year. In April, the company introduced GPT-Rosalind, a specialized model built for complex tasks in biology, chemistry, and drug discovery. OpenAI's API pricing page recently listed a new model, gpt-rosalind-discovery, priced at $5 per million input tokens — the research version began billing earlier this month and is available only to approved institutions, reportedly including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific.
OpenAI is also working with pharmaceutical manufacturers Novo Nordisk and Moderna to integrate AI into drug research and development. Bringing Orchestra's workflow software into Rosalind extends the offering from scientific research tools into drug-program operations — agents that coordinate studies, vendors, and timelines, making the suite useful beyond the lab.
A lab race with Anthropic
The deal is another move in the race among top AI labs to prove their systems matter beyond chatbots and coding tools. Anthropic has been pushing into scientific research in parallel, and the messaging from OpenAI is clear: in science and medicine, the pitch is not just faster workflows but changing how research gets done in industries that move slowly and cost billions to advance new treatments.
That slowness is the opportunity. Developing a new drug typically takes 10 to 15 years, and OpenAI expects AI to help shorten that timeline. Buying Orchestra signals that the company believes the bottleneck is not only in discovering compounds — it is in managing the programs that carry them through trials, vendors, and timelines. If agents can coordinate that machinery, the payoff is measured in years, not minutes.
By Hamza Faisal
